Descripción del proyecto
Un tratamiento inyectable, dirigido y fotoactivado contra el hiperinsulinismo congénito
Las células del organismo se «alimentan» de la glucosa producida por la digestión de los hidratos de carbono. Cuando aumenta la glucemia, las células β del páncreas liberan insulina, que permite al organismo absorber la glucosa. Tanto la hiperglucemia como la hipoglucemia pueden causar problemas. El hiperinsulinismo congénito es una afección de los recién nacidos y lactantes causada por una sobreproducción de insulina, que provoca una glucemia peligrosamente baja y lesiones encefálicas hipoglucémicas. En la actualidad, no existe ningún tratamiento disponible sin graves efectos secundarios, continuos problemas de salud y una tremenda carga económica. El equipo del proyecto LightCure, financiado con fondos europeos, pretende demostrar que su tratamiento fotodinámico, dirigido e inyectable puede eliminar las células β hiperfuncionantes de forma segura y eficaz, lo que permitirá una vida normal a los bebés y sus familias.
Objetivo
Congenital hyperinsulinism (CHI) is a group of rare diseases of newborns and infants with functionally defective nonneoplastic beta-cells that cause hypoglycemia and severe morbidity through oversecretion of insulin. CHI is a major cause of hypoglycemic brain injury with intellectual disability, epilepsy and cerebral palsy. As no registered causal therapy exists, management of CHI aims at increasing blood glucose levels causing severe side effects in all patients while life-threatening frequent hypoglycaemias remain. Removal of hyperfunctioning beta cells by pancreatectomy leads to insulin dependent diabetes mellitus (IDDM) and maldigestion of food, changing one disease for another with severe secondary morbidity. Management of CHI is choosing between evils and symptomatic management is partially effective in only some sub-types. CHI also represents a major burden for families, because of disability but also as a result of continuous monitoring and correction of glucose levels for many years, requiring permanent alertness. Health problems and economic decline occur in most parents. A normal life is not feasible for families with babies with CHI. LightCure consortium partners have demonstrated the feasibility of selectively targeting beta cells using exendin 4 (EX) labelled with a photosensitizer (700DX) specifically binding to beta cells. This photosensitizer can be activated by light of a certain wavelength and will produce radical oxygen species leading to cell damage, a principle called targeted photodynamic therapy (tPDT). In this project we will build on existing cutting-edge technology exclusively available to the consortium partners and perform human proof of concept studies demonstrating safety and efficacy of tPDT with EX700DX. We will deliver the proof-of-concept that after injection of EX700DX, minimally invasive tPDT leads to normalization of blood glucose levels avoiding morbidity, enabling a normal life for babies with CHI and their families.
Ámbito científico
Palabras clave
Programa(s)
Tema(s)
Convocatoria de propuestas
HORIZON-HLTH-2022-DISEASE-06-two-stage
Consulte otros proyectos de esta convocatoriaRégimen de financiación
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinador
6525 GA Nijmegen
Países Bajos